更正：旨在完全抑制新冠肺炎患者肺部严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的协同药物组合。
Correction: Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients.
作者信息
De Forni Davide, Poddesu Barbara, Cugia Giulia, Pagnozzi Daniela, Chafouleas James, Lisziewicz Julianna, Lori Franco
出版信息
PLoS One. 2024 Dec 5;19(12):e0315297. doi: 10.1371/journal.pone.0315297. eCollection 2024.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0276751.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0276751。]
相似文献
1
Correction: Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients.更正：旨在完全抑制新冠肺炎患者肺部严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的协同药物组合。
PLoS One. 2024 Dec 5;19(12):e0315297. doi: 10.1371/journal.pone.0315297. eCollection 2024.
2
Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients.旨在完全抑制新冠病毒肺炎患者肺部严重急性呼吸综合征冠状病毒2的协同药物组合。
PLoS One. 2022 Nov 10;17(11):e0276751. doi: 10.1371/journal.pone.0276751. eCollection 2022.
3
Correction: Comparing methods to classify admitted patients with SARS-CoV-2 as admitted for COVID-19 versus with incidental SARS-CoV-2: A cohort study.更正：比较将新型冠状病毒2型（SARS-CoV-2）确诊患者分类为因冠状病毒病2019（COVID-19）入院与SARS-CoV-2偶发感染入院的方法：一项队列研究。
PLoS One. 2025 Mar 18;20(3):e0320617. doi: 10.1371/journal.pone.0320617. eCollection 2025.
4
Correction: Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection?更正：门诊患者中的新冠病毒病——发热是严重急性呼吸综合征冠状病毒2感染的有用指标吗？
PLoS One. 2021 May 6;16(5):e0251623. doi: 10.1371/journal.pone.0251623. eCollection 2021.
5
Correction: SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria.更正：保加利亚前三次主要新冠疫情浪潮期间的新冠病毒再次感染情况。
PLoS One. 2025 Jan 24;20(1):e0318435. doi: 10.1371/journal.pone.0318435. eCollection 2025.
6
Correction: Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.更正：轻度和重度新冠病毒感染后针对严重急性呼吸综合征冠状病毒2的血清IgG反应及IgG无反应者分析
PLoS One. 2021 Oct 4;16(10):e0258401. doi: 10.1371/journal.pone.0258401. eCollection 2021.
7
Correction: Evaluation of the diagnostic performance of PanbioTM Abbott SARS-CoV-2 rapid antigen test for the detection of COVID-19 from suspects attending ALERT center.更正：评估PanbioTM雅培SARS-CoV-2快速抗原检测对来自ALERT中心可疑人员的COVID-19检测的诊断性能。
PLoS One. 2024 Jul 12;19(7):e0307338. doi: 10.1371/journal.pone.0307338. eCollection 2024.
8
Correction: Scientific quality of COVID-19 and SARS CoV-2 publications in the highest impact medical journals during the early phase of the pandemic: A case control study.更正：大流行早期高影响力医学期刊中关于COVID-19和SARS-CoV-2出版物的科学质量：一项病例对照研究。
PLoS One. 2021 Apr 8;16(4):e0250141. doi: 10.1371/journal.pone.0250141. eCollection 2021.
9
Correction: Comparative analysis of various clinical specimens in detection of SARS-CoV-2 using rRT-PCR in new and follow up cases of COVID-19 infection: Quest for the best choice.更正：在新冠病毒感染的新发病例和随访病例中使用逆转录实时荧光定量聚合酶链反应检测严重急性呼吸综合征冠状病毒2的各种临床标本的比较分析：寻找最佳选择。
PLoS One. 2021 Jun 10;16(6):e0253355. doi: 10.1371/journal.pone.0253355. eCollection 2021.
10
Correction: Seroprevalence and longevity of SARS-CoV-2 nucleocapsid antigen-IgG among health care workers in a large COVID-19 public hospital in Saudi Arabia: A prospective cohort study.更正：沙特阿拉伯一家大型新冠肺炎公立医院医护人员中SARS-CoV-2核衣壳抗原-IgG的血清阳性率和持续时间：一项前瞻性队列研究。
PLoS One. 2024 Jun 6;19(6):e0305375. doi: 10.1371/journal.pone.0305375. eCollection 2024.
本文引用的文献
1
Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients.旨在完全抑制新冠病毒肺炎患者肺部严重急性呼吸综合征冠状病毒2的协同药物组合。
PLoS One. 2022 Nov 10;17(11):e0276751. doi: 10.1371/journal.pone.0276751. eCollection 2022.
Zotero 插件